Dexamethasone IV
Phase 3Small molecule
Dexamethasone IV is one of 44 small molecule programs targeting Nausea and vomiting. It is currently in Phase 3.
2
Indications
5
Total Trials
2
Active Trials
43
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
78 competitors in Nausea and Vomiting
#DrugCompanyPhaseTrials
1Zyprexa
MMODAG GmbH
Approved
Xylocaine
MMEDRx USA, Inc.
Approved
Duragesic
CCephalon
Approved
Zithromax
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Thalomid
Bristol-Myers SquibbPhase 3
Megace
Bristol-Myers SquibbPhase 3
Abraxane
Bristol-Myers SquibbPhase 3
Gemzar
Johnson & JohnsonPhase 3
Nereus
VVanda Pharmaceuticals
Phase 3
Dexamethasone IV
MMayo Clinic
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Nausea and vomiting2 trials
Dexamethasone Dose for Postoperative Nausea and Vomiting Prophylaxis in Obese Patients
Unknown status·—·Phase 4·NCT04538820·150 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Dexamethasone IV. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- MMayo Clinic